Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mortality worldwide. Recent studies have clearly highlighted the critical role of the immuno-inflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both interleukin (IL)-17 and IL-10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL-17-dependent reduction in lesion development and vascular inflammation. In vivo administration of IL-17 reduces endothelial vascular cell adhesion molecule-1 expression and vascular T cell infiltration, and significantly limits atherosclerotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL-17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and ac... 
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The immunoinflammatory response plays a prominent role in driving atherosclerotic lesion development, progression, and complications (Binder et al., 2002; Hansson and Libby, 2006; Tedgui and Mallat, 2006; Weber et al., 2008) . Defining the direct roles of specific immune regulatory pathways in the modulation of ath erosclerosis is certainly of considerable interest (Tedgui and Mallat, 2006) .
Suppressor of cytokine signaling (SOCS) pro teins are key physiological regulators of both innate and adaptive immunity, and control the development of various immunoinflammatory diseases (Yoshimura et al., 2007) . SOCS3 is ex pressed in atherosclerotic lesions, and the cur rent paradigm suggests an atheroprotective role through inhibition of STAT3 signaling and the suppression of proinflammatory responses (Tang et al., 2005; Gharavi et al., 2007; OrtizMuñoz et al., 2009 ). However, its direct role in the control of the immune response of atheroscle rosis is still largely unknown.
Recent studies have addressed the role of T cell-specific SOCS3 expression on T cell differentiation and cytokine production. In triguingly, one study reported preferential Th3 and/or Tr1like differentiation and reduced Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mor tality worldwide. Recent studies have clearly highlighted the critical role of the immuno inflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both inter leukin (IL)17 and IL10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL17-dependent reduction in lesion development and vascular inflammation. In vivo administration of IL17 reduces endothelial vascular cell adhesion molecule-1 expression and vascular T cell infiltration, and significantly limits atheroscle rotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and activator of transcription (STAT) 3 phosphorylation and IL17 are associ ated with a stable plaque phenotype. These results identify novel SOCS3controlled IL17 regulatory pathways in atherosclerosis and may have important implications for the under standing of the increased susceptibility to vascular inflammation in patients with domi nantnegative STAT3 mutations and defective Th17 cell differentiation.
2068
SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
mice (Seki et al., 2003) . As expected, we found reduced PSTAT3 in SOCS3Tg T cells (unpublished data). After 6 wk of a high fat diet, spleenderived CD4 + cells of mice transferred with CD4 + SOCS3Tg cells showed reduced pro duction of IL17 and IL10 but enhanced production of IL4 (Fig. S1 e) . This is consistent with previous studies that showed reduced Th17 and preferential Th2 cell differentiation of T cells isolated from SOCS3Tg mice (Seki et al., 2003; Tanaka et al., 2008) . Interestingly, we found a fourfold in crease of lesion size in Apoe / /Rag2 / mice transferred with CD4 + SOCS3Tg cells compared with controls (Fig. S1 e) , de spite similar plasma cholesterol levels (12.1 ± 1.6 vs. 14.1 ± 0.78 g/liter; P = 0.25). Thus, SOCS3 expression in T cells significantly affects atherosclerotic lesion development.
SOCS3 deletion in T cells enhances IL10 and IL17 production
The reduction of atherosclerosis in SOCS3cKO mice was associated with a significant decrease of T cell infiltration within the lesions (Fig. 1 b) , suggesting a modulation of the T cell phenotype. We found no difference in the number and suppressive function of natural CD4 + CD25 + Foxp3 + regula tory T cells between the two groups of mice (Fig. S2) . Thus, we analyzed cytokine production by purified spleenderived CD4 + cells. We observed a significant reduction of IFN production and an increase of IL10 by cells recovered from SOCS3cKO mice (Fig. 1 c) , which was consistent with pre vious results showing preferential Th3 and/or Tr1like dif ferentiation and reduced Th1 polarization in mice lacking SOCS3 expression in T cells (Kinjyo et al., 2006) . However, we also detected a threefold increase in IL17 production by the purified SOCS3deficient CD4 + cells compared with controls, consistent with the critical role of STAT3 activation in Th17 development (Fig. 1 c; Chen et al. 2006; Dong, 2008) . Flow cytometry analysis on freshly isolated cells showed no cells expressing both IL17 and IL10, suggesting that in vivo, IL10 and IL17 are produced by distinct T cells, which is in agreement with a recent study showing that RORt + T cells producing both IL10 and IL17 could not be observed in vivo (Lochner et al., 2008) . Consistent with enhanced IL17 production, we found increased IL6 but re duced IL27 levels in the circulating blood of SOCS3cKO mice (Fig. S2 c) . We also found increased production of IL6 by cultured SOCS3cKO splenocytes. IL6 neutralization did not alter IL17 production, indicating that the Th17 pro file of SOCS3cKO cells was independent of IL6 ( Fig. S2 d) . Thus, our results indicate that in the absence of SOCS3 ex pression in T cells, there is a preferential switch toward increased production of both IL10 and IL17, which helps explain seemingly divergent previous results on Th3, Tr1, and Th17 cells.
SOCS3 deletion in T cells induces an antiinflammatory phenotype in macrophages
It was remarkable that the loss of SOCS3 in one cell type has produced significant effects on lesion development, where Th1 polarization in mice lacking SOCS3 expression in T cells (Kinjyo et al., 2006) . However, others have reported a preferential promotion of Th17 in the absence of T cellspecific SOCS3 expression (Chen et al., 2006) , consistent with the critical role of STAT3 activation in Th17 devel opment (for review see Dong, 2008) . Tr1related responses have been associated with the reduction of atherosclerosis (Maron et al., 2002; Mallat et al., 2003) , whereas recent studies have indirectly associated IL17 production with potentially proatherogenic responses (Eid et al., 2009) . Still, the direct roles of SOCS3 and IL17 production in the modulation of vascular inflammation and atheroscle rotic lesion development remain unknown. The involve ment of SOCS3 and IL17-related signaling pathways in various inflammatory diseases (Bettelli et al., 2007; Yoshimura et al., 2007) will certainly promote the devel opment of therapeutic strategies aiming at the modulation of these pathways to limit disease severity and progression. Whether modulation of SOCS3 and IL17 production would similarly alter the inflammatory process related to atherosclerosis remains unknown. We have therefore de signed a series of experiments to directly assess the roles of T cell-specific SOCS3 and (SOCS3controlled) IL17 in the modulation of vascular inflammation and atheroscle rotic lesion development.
RESULTS AND DISCUSSION SOCS3 expression in T cells significantly affects atherosclerotic lesion development
We first examined the effect of SOCS3 deletion in T cells on the development of atherosclerosis. We reconstituted lowdensity lipoprotein receptor-deficient (Ldlr / ) mice with either a WT bone marrow from SOCS3flox/flox mice (the reconstituted mice are designated SOCS3WT) or a bone marrow from mice with T cell-specific deletion in SOCS3 (SOCS3flox/flox:LckCre) generated by a condi tional gene targeting approach using a CreloxP system (des ignated SOCS3cKO; Yasukawa et al., 2003; Kinjyo et al., 2006) . Phosphorylated (P)STAT3 was readily detectable in atherosclerotic lesions, and we found a marked increase in PSTAT3 in spleenderived T cells from SOCS3cKO mice compared with SOCSWT mice (Fig. S1 ), indicating an ef ficient and functional deletion of SOCS3 in T cells. We therefore quantified lesion size after 6 wk on a high fat diet. We found an unexpected 50% reduction of aortic sinus lesion size in SOCS3cKO mice compared with controls ( Fig. 1 a) , despite similar plasma cholesterol levels (18.4 ± 0.7 vs. 17.6 ± 0.5 g/liter; P = 0.32). We observed a similar protection against atherosclerosis at the levels of the aortic sinus and the descending thoracic aorta in a separate set of old Ldlr / mice reconstituted with SOCS3cKO bone marrow (Fig. S1 d) .
We then tested the effect of SOCS3 overexpression in T cells on the development of atherosclerosis (Fig. S1 e) 
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were incubated in the presence of SOCS3cKO CD4 + cells compared with SOCS3WT CD4 + cells (Fig. 1 e) . Macro phage death within the lesions is highly promoted by proin flammatory signals. We found a significant reduction of IL12 and an increase in IL10 production by macrophages after coincubation with SOCS3cKO CD4 + cells compared with coincubation with SOCS3WT CD4 + cells (Fig. 2 a) . In ad dition, we found a significant reduction in the expression of NOS2 and TNF, and an increase of arginase1 after coincu bation of macrophages with SOCS3cKO T cells compared with SOCS3WT cells, consistent with a limitation of M1 phenotype and the preservation of an antiinflammatory po tential (Fig. 2 a) . These effects persisted when T cells and macrophages were physically separated using Transwells, suggesting the involvement of soluble factors (Fig. 2 a) . Neu tralization of IL10 production and, to a lesser extent IL17, prevented some of the antiinflammatory effects (Fig. 2 , c and d), many other cell types are involved. Thus, we hypothesized that the T cell cytokine profile induced by SOCS3 dele tion may modulate the inflammatory response of other cell types. In this regard, the innate immune system plays a critical role in atherogenesis (Hansson and Libby, 2006) . Therefore, we examined the impact of SOCS3 deletion in T cells on macrophage infiltration and activation. The extent of lesion macrophage accumulation was not altered in SOCS3cKO compared with SOCS3WT mice (35,022 ± 6,308 vs. 36,635 ± 5,223 µm 2 ; P = 0.84). We hypothesized that this could be related to a differential modulation of macrophage survival within the lesions. Interestingly, we found a marked reduction in the size of the necrotic core in lesions of SOCS3 cKO mice (Fig. 1 d) . This was confirmed by the reduction of lesion Tdtmediated dUTPbiotin nickend labeling (TUNEL) staining (unpublished data) and a protection against macro phage apoptosis when bone marrow-derived macrophages with a study showing that STAT3 activity in tumor cells mediates immune evasion through blockade of inflammatory signal production by the innate and adaptive immune system (Wang et al., 2004) . Further studies will be necessary to iden tify the soluble factors responsible for the full change in macrophage phenotype.
whereas incubation with IL10 was associated with an anti inflammatory phenotype that persisted after supplementation with IL17 (Fig. 2 e) . Our results indicate that SOCS3 sig naling in T cells not only affects the T cell phenotype but also regulates the production of pro and antiinflammatory/ atherogenic mediators by macrophages. This is consistent treated with either a mouse monoclonal anti-IL17A neu tralizing antibody (Uyttenhove and Van Snick, 2006; Uyttenhove et al., 2007) or an isotypematched control for 6 wk (see Materials and methods). Interestingly, neutraliza tion of IL17 did not alter lesion size in SOCS3WT mice, which are highly Th1 biased and produce low levels of IL17, but totally abrogated the atheroprotective effect of T cell-specific SOCS3 deletion and led to a marked in crease of lesion formation (Fig. 3, a and c) . Acceleration of lesion development was associated with a marked increase in vascular inflammation, as revealed by increased vascular cell adhesion molecule (VCAM)-1 expression (Fig. 3 f) , marked T cell infiltration within the lesions and the adventitia of Neutralization of IL17 abrogates atheroprotection in mice with T cell-specific SOCS3 deletion and enhances vascular inflammation The reduction of atherosclerosis in SOCS3cKO mice was associated with a reduction in IFN and an increase in both IL10 and IL17. The pro and antiatherogenic roles of IFN and IL10, respectively, have been extensively addressed in previous studies (Tedgui and Mallat, 2006) . However, the role of IL17 in atherosclerosis is still un explored. Thus, we examined the direct role of IL17 pro duction in the atheroprotective effect of T cell-specific SOCS3 deletion. We generated additional series of chime ric Ldlr / mice that were put on a high fat diet and were on a C57BL/6 background) and that supplementation of SOCS3WT mice with IL17 might inhibit lesion devel opment. Thus, we fed 17wkold female Ldlr / mice a high fat diet and treated them with either rIL17 or control mouse serum albumin. Administration of rIL17 led to a significant elevation of circulating IL17 levels (Fig. S3 c) and to a moderate but significant elevation of IL6 produc tion (27.5 ± 18.7 vs. 1 ± 0.6 pg/ml; P = 0.008) compa rable to levels detected in SOCS3cKO mice, suggesting biological effects. We found no change in T cell cytokine profile (Fig. S3 d) or splenocyte inflammatory response (unpublished data) in mice treated with rIL17, indicating that at this dosage, IL17 did not promote inflammatory cell activation. Interestingly, we found a significant reduc tion of atherosclerotic lesion development in mice supple mented with rIL17 (Fig. 4 a) . We reproduced the results in a different set of younger 12wkold female Ldlr / mice (Fig. 4 a) . Of note, atheroprotection was associated with a marked inhibition of vascular inflammation as revealed by a significant inhibition of vascular T cell infiltration (Fig. 4 b) and a 60% reduction of endothelial VCAM1 expression (Fig. 4 c) . rIL17 also reduced IL1-induced endothelial VCAM1 expression in vitro (Fig. 4 d) . These results in dicate that IL17 inhibits high fat-induced vascular inflam mation and atherosclerotic lesion development.
anti-IL17-treated SOCS3cKO mice (Fig. 3, b and d) , and a switch toward reduced IL10 and increased IL4 production by spleenderived CD4 + cells (Fig. 3 e) but no change in IFN (15.4 ± 0.5 vs. 12.7 ± 1.1 ng/ml in SOCS3WT and SOCS3cKO, respectively). Regulatory T cell function was not altered by anti-IL17 treatment (not depicted), and the proatherogenic effect of IL17 neu tralization in SOCS3cKO mice was not prevented by IL10 supplementation (Fig. S3) . These results identify an un precedented role for SOCS3controlled IL17 in the con trol of vascular inflammation and T cell accumulation within atherosclerotic lesions, which profoundly affects lesion de velopment. Our results are in agreement with a study show ing that IL17 neutralization was associated with enhanced T cell infiltration in a model of allergic asthma (Schnyder Candrian et al., 2006) .
In vivo administration of IL17 to Ldlr / mice reduces endothelial VCAM1 expression, vascular T cell infiltration, and atherosclerotic lesion development Neutralization of IL17 accelerated atherosclerosis in SOCS3 cKO mice but had no effect on lesion development in SOCS3WT mice (Fig. 3) . We reasoned that this apparent discrepancy might be caused by the low level of IL17 production by SOCS3WT T cells (highly Th1 biased 
the detection of IL17 in normal mouse aorta by Western blotting using a different antibody (unpublished data). These results show that C57BL/6 Ldlr / mice, which are Th1 biased, produce low levels of IL17 in T cells and that vas cular wall production of IL17 decreases during the devel opment of atherosclerosis, suggesting a relationship between SMC differentiation and IL17 expression.
Finally, we studied human carotid atherosclerotic arteries retrieved from patients undergoing carotid endarterectomy. Patients characteristics are given in Table S1 . PStat3 and IL17 expression were readily detectable in CD3 + cells of human plaques (Fig. 6) , although not all CD3 + cells expressed IL17 or PStat3 (Fig. 6) . We could also detect PStat3 in other cell types, as expected (Fig. 6, and not depicted) . Inter estingly, we also detected IL17 expression in vascular SMCs, and consistent with our data in mice, we found a clear
Vascular expression of IL17 and PStat3 is associated with plaque stability
We then examined IL17 expression in mouse atheroscle rotic arteries (Ldlr / mice reconstituted with SOCS3WT or SOCS3cKO) using immunohistochemistry. As ex pected, we were unable to detect IL17 expression in T cells of SOCS3WT mice (not depicted), and only occa sional IL17 + inflammatory cells were detected in lesions of SOCS3cKO mice (Fig. 5, left, a and b) , which may be ex plained, at least in part, by the low number of activated SOCS3deficient T cells that infiltrated the lesions. Un expectedly, we found a marked staining of IL17 in medial smooth muscle cells (SMCs) of plaquefree areas (which was confirmed in normal arteries; Fig. 5, left, e) , and the staining appeared to be rapidly lost in medial SMCs under lying early lipid lesions (Fig. 5, left, c and d) . We confirmed In conclusion, we show that endogenous expression of SOCS3 in T cells interrupts a major regulatory pathway in atherosclerosis through inhibition of IL17 production. Inter estingly, patients have been identified with defective STAT3 signaling (Minegishi et al., 2007) and IL17 production (Ma et al., 2008; Milner et al., 2008) , and recent observational studies have reported the abnormal occurrence of vascular in flammation (van der Meer et al., 2006; Ling et al., 2007) in this setting despite the absence of classical cardiovascular risk factors. Although the reported vascular abnormalities con sisted mainly of inflammatory vascular aneurysms, some cases decrease in its expression by medial SMCs underlying ad vanced lesions (Fig. 5, right) . Interestingly, semiquantitative assessment of PStat3 and IL17 expression showed increased levels of these two markers in plaques with fibrous (stable) compared with atheromatous (unstable) phenotype (Fig. 6) . Consistent with this finding, increased levels of PStat3 were significantly associated with a low macrophage content, and increased levels of IL17 were associated with a lower mac rophage infiltration and a higher SMC content (Fig. 6) . No relation was found between Stat3 or PStat1 levels and plaque phenotype (unpublished data). Western blot analysis. CD4 + cells were stimulated with coated antiCD3 and antiCD28 antibodies (2 µg/ml each) for 60 min. Cells were then pro cessed for Western blot analyses. Membranes were probed with antibodies directed against SOCS3 (clone 1B2; MBL International), PStat3 and Stat3 protein (Cell Signaling Technology). On saphenous vein endothelial cell ex tracts, we quantified VCAM1 expression by using a specific antibody (R&D Systems). On human plaque extracts, PStat3, Stat3, and PStat1 staining was performed using specific antibodies purchased from Cell Signaling Technol ogy. Human IL17 was detected using a monoclonal antibody (clone 41802; R&D Systems).
T cell-macrophage co-cultures. Macrophages were prepared from mouse bone marrow. Differentiated macrophages were then cultured in 6well plates either without T cells or with WT or SOCS3cKO T cells (10 6 cells per well) for 24 h in the presence of 1 µg/ml of soluble antiCD3 anti body, after which the T cells were removed and the different cultures were washed twice with PBS and the macrophages were stimulated for 24 h with 1 µg/ml LPS and 100 U/ml IFN. In some experiments, SOCS3WT or SOCS3cKO T cells were incubated in the presence of the neutralizing antibodies anti-IL10 (2 µg/ml; R&D Systems) or antiIL17 (10 µg/ml; Uyttenhove and Van Snick, 2006) , or their corresponding isotypematched controls. In other experiments, 10 ng/ml of the recombinant proteins IL10 and/or IL17 (eBioscience) were added on macrophages for 24 h. Quantita tive realtime PCR was performed on an ABI PRISM 7700 (Applied Bio systems) in triplicates. Cycle threshold for GAPDH (primers: GAPDHR, 5CGTCCCGTAGACAAAATGGTGAA3; GAPDHL, 5GCCGT GAGTGGAGTCATACTGGAACA3) was used to normalize gene ex pression. Primer sequences of M1 macrophage markers (NOS2 and TNF) and M2 marker (arginase1) are as follows: NOS2R, 5CCAAGCCCTCA CCTACTTCC3; NOS2L, 5CTCTGAGGGCTGACACAAGG3; TNF-R, 5GTAGCCCACGTCGTAGCAAAC3; TNF-L, 5CTG GCACCACTAGTTGGTTGTC3; Arg1-R, 5CTCCAAGCCAAA GTCCTTAGAG3; Arg1-L, 5AGGAGCTGTCATTAGGGACATC3). PCR conditions were 10 min at 95°C; 35 cycles of 95°C for 15 s, 60°C for 20 s, and 72°C for 20 s; and a final extension at 72°C for 20 s. On superna tants, ELISAs were performed to measure IL10 and IL12 (BD) of the different conditions. TUNEL staining was performed on macrophages to analyze apoptosis.
Human carotid plaques. The processing and examination of the dissected atherosclerotic plaques has been described previously (Ho et al., 1995; Verhoeven et al., 2004) . All stainings were examined microscopically and plaque characteristics were scored semiquantitatively, as described previously (Verhoeven et al., 2004) . In brief, no or minor (categorized as "low") mac rophage and SMC infiltration represents absent or minimal staining with few clustered cells, whereas moderate and heavy represent moderate or heavy staining with larger areas of clustered cells (categorized as "high"). The size of the lipid core was estimated as a percentage of total plaque area with a di vision in three categories: <10% (fibrous plaques), 10-40% (fibroatheromatous plaques), and >40% (atheromatous plaques). Recently, we have demonstrated that our semiquantitative analysis of atherosclerotic plaque histology is well reproducible, both intra and interobserver (Hellings et al., 2007) . 40 carotid atherosclerotic plaques (Table S1 ) were used for determination of PStat3, Stat3, PStat1, Stat1, and IL17 expression. Some of these were also used for immunohistochemical staining. The plaques were from the AtheroExpress study, a longitudinal vascular biobank study in which participants provided written informed consent, and the study was approved by the Medical Ethics Committee of the University Medical Center Utrecht. Other plaques used for immunohistochemical staining were previously described (Boddaert et al., 2005) . of coronary atherosclerosis have been reported in these young individuals . Thus, our results may have important implications for the understanding of the patho physiological mechanisms of vascular inflammation in humans and identify novel targets for disease modulation.
MATERIALS AND METHODS

Animals.
We subjected 12 or 24wkold C57BL/6 Ldlr / female mice to medullar aplasia by 9.5 Gy of lethal total body irradiation. We repopu lated the mice with an intravenous injection of bone marrow cells isolated from femurs and tibias of female C57BL/6 SOCS3WT mice (SOCS 3flox/flox) or littermate mice with a T cell-specific deletion in SOCS3 (SOCS3flox/flox:LckCre) generated by a conditional gene targeting ap proach using a CreloxP system (Yasukawa et al., 2003) . The SOCS3fl/ flLckCre mice were 87.5% C57BL/6 and 12.5% 129 and were inter crossed for >10 generations, indicating that they were on a homogeneous background. After 4 wk of recovery, mice were fed a high fat diet contain ing 15% fat, 1.25% cholesterol, and 0% cholate for 6 wk. In some experi ments, the reconstituted mice received an i.p. injection of either purified neutralizing anti-IL17A-specific antibody (200 µg/mouse, twice per week; Fig. S4 ; Uyttenhove and Van Snick, 2006; Uyttenhove et al., 2007) or IgG1 control for 6 wk. In others experiments using anti-IL17A antibody or IgG control, we injected i.p. the reconstituted SOCS3flox/flox:Lck Cre mice with recombinant mouse IL10 (eBioscience) diluted in PBS 0.05% mouse albumin (2 µg/mouse, twice per week) or PBS 0.05% albu min for 6 wk. In another set of experiments, we treated i.p. 12 or 17wk old C57BL/6 Ldlr / female mice with recombinant mouse IL17A (eBioscience) diluted in PBS 0.05% mouse albumin (2 µg/mouse, twice per week) or PBS 0.05% albumin during 5 wk of a high fat diet. Finally, 6wkold male C57BL/6 Apoe / /Rag2 / mice (provided by P. Gourdy, Institut National de la Santé et de la Recherche Médicale, Toulouse, France) were transferred intravenously with 3 × 10 6 CD4 + cells recovered from either C57BL/6 SOCS3WT or C57BL/6 SOCS3overexpressing Tg (SOCS3Tg; Seki et al., 2003) , and were put on high fat diet for 6 wk. Experiments were conducted according to the French veterinary guide lines and those formulated by the European Community for experimental animal use (L35886/609EEC), and were approved by the Institut Na tional de la Santé et de la Recherche Médicale.
Extent and composition of atherosclerotic lesions. Quantification of lesion size and composition was performed as previously described (Taleb et al., 2007) . TUNEL staining was performed on fixed cryostat sections as previously described . Anti-mouse VCAM1 anti body (clone 429) was obtained from BD. Tyrosine 705 phosphorylation of Stat3 was detected in the plaque using rabbit anti-PStat3 antibody (Cell Signaling Technology). IL17 staining in the plaque was performed using a validated anti-human/mouse IL17 antibody from Santa Cruz Biotechnol ogy, Inc. (Takahashi et al., 2008) . The IL17A-deficient mice were pro vided by Y. Iwakura (University of Tokyo, Tokyo, Japan).
Cell recovery and purification, culture, proliferation, and cytokine assays. CD11c + , CD4 + CD25 + , and CD4 + CD25 -cells were purified and processed for cell proliferation assays and cytokine production as previously described in detail (Taleb et al., 2007) . In some experiments (Fig. S3 ), 2 × 10 5 CD4 + T cells per well were stimulated in antiCD3-coated (2 µg/ml) and antiCD28-coated (2 µg/ml) microplates for 48 h in the absence of CD11c + cells. IL4, IL10, IL17, and IFN productions in the superna tants were measured using specific ELISAs (BD and R&D Systems).
Flow cytometry. Splenocytes were labeled with FITCconjugated anti CD4 (clone GK1.5; Miltenyi Biotec), and intracellular Foxp3 staining was performed using PEconjugated anti-mouse/rat Foxp3 (PFJK16s; eBiosci ence) according to the manufacturer's instructions (eBioscience). Anti-P Stat3 staining was performed on CD4 + T cells stimulated with 100 ng/ml on March 20, 2012 jem.rupress.org
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Statistical analysis. Values are expressed as means ± SEM. Differences between values were examined using nonparametric MannWhitney or KruskalWallis tests and were considered significant at P < 0.05. Fig. S1 shows the efficiency of SOCS3 deletion and the effects of SOCS3 deletion or overexpression in T cells on atherosclerosis. Fig. S2 shows regulatory T cell number and function, and cytokine levels in chimeric SOCSWT and SOCS3cKO mice. Fig. S3 shows complementary IL10 and IL17 supplementation experiments. Fig. S4 shows characterization of the MM17F3 anti-IL17 antibody. Table S1 shows patient characteristics. Online supplemental material is available at http:// www.jem.org/cgi/content/full/jem.20090545/DC1.
Online supplemental material.
